Fluidic Sciences Acquires Business And Assets Of Sphere Bio To Accelerate Single-cell And Protein Interaction Discovery

Fluidic Sciences Ltd, a leader successful in‑solution macromolecule relationship analysis, coming announced it has purchased nan business and assets of Sphere Bio Ltd. The transaction creates a powerful, complementary exertion suite that enables researchers to seamlessly traverse cellular usability and molecular binding, accelerating biotherapeutic find and development.

Sphere Bio's proprietary picodroplet systems and Cyto‑Mine Chroma multiplexing level present rapid, high‑fidelity, single‑cell screening, isolation, and monoclonality assurance. These capabilities align pinch Fluidic Sciences' Microfluidic Diffusional Sizing (MDS) platform—an immobilization‑free, in‑solution attack that measures binding affinity (Kd), stoichiometry, and attraction straight successful analyzable matrices—to connection a uniquely integrated workflow from compartment to molecular mechanism.

Fluidic Sciences will merge Sphere Bio's teams complete nan coming months, aligning roadmap priorities and maintaining uninterrupted customer support. In nan contiguous term, some brands will proceed successful market; a unified solutions roadmap and cross‑workflow exertion notes will follow.

This is simply a highly strategical fit. Sphere Bio's technologies widen our scope upstream into high‑throughput functional compartment screening, while our in‑solution biophysics deepens downstream molecular characterization. The mixed worth proposition strengthens our position crossed antibody engineering, compartment statement development, and compartment therapy."

Mark Gilligan, Board Member, Fluidic Sciences

Dr. James Wilkinson, CEO, Fluidic Sciences, added: "By bringing Sphere Bio into Fluidic Sciences, we're pairing high‑throughput functional compartment screening pinch definitive in‑solution relationship measurements—creating an end‑to‑end workflow that accelerates find and de‑risks development."

We are excited to harvester our single-cell expertise pinch Fluidic Sciences' in-solution technologies to present integrated solutions that accelerate discovery. Within Fluidic Sciences, we'll proceed innovating and expanding applications for picodroplets and Cyto‑Mine Chroma—now connected to powerful in‑solution biophysics."

Richard Hammond, CTO, Sphere Bio